Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154697 · ClinicalTrials.gov registry record
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
A clinical trial of Sleep Disturbances in Smith-Magenis Syndrome, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03154697 is a study of Sleep Disturbances in Smith-Magenis Syndrome that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03154697, a study of Sleep Disturbances in Smith-Magenis Syndrome, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.
Conditions Studied
Interventions
- OTHER Data collection of sleep disturbances in individuals with SMS
Study Locations (1)
District of Columbia
- Vanda Pharmaceuticals - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-01 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154697
The ClinicalTrials.gov registry entry for NCT03154697 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sleep Disturbances in Smith-Magenis Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Data collection of sleep disturbances in individuals with SMS is the first listed.
NCT03154697 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03154697 about?
NCT03154697 is a clinical study titled "Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances". This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.
What is the current status of trial NCT03154697?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2016-01. Estimated completion is 2030-12.
What conditions does trial NCT03154697 study?
This clinical trial studies the following conditions: Sleep Disturbances in Smith-Magenis Syndrome.
What interventions are being tested in trial NCT03154697?
The interventions under investigation include: Data collection of sleep disturbances in individuals with SMS (OTHER).
Who is sponsoring clinical trial NCT03154697?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03154697 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.